RT Journal Article
SR Electronic
T1 Estimated SARS-CoV-2 Seroprevalence in Children and Adolescents in Mississippi, May Through September 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.05.21250792
DO 10.1101/2021.02.05.21250792
A1 Charlotte V. Hobbs
A1 Jan Drobeniuc
A1 Theresa Kittle
A1 John Williams
A1 Paul Byers
A1 Subbian S. Panayampalli
A1 Meagan Stephenson
A1 Sara S. Kim
A1 Manish M. Patel
A1 Brendan Flannery
A1 CDC COVID-19 Response Team
A1 CDC COVID-19 Task Force Microbial Pathogenesis and Immune Response Laboratory.
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.05.21250792.abstract
AB Case-based tracking of COVID-19 in children and adolescents may underestimate infection, and compared with adults there is little pediatric SARS-CoV-2 seroprevalence data. To assess evidence of previous SARS-CoV-2 infections among children and adolescents in Mississippi, serologic testing for antibodies to SARS-CoV-2 was conducted on a convenience sample of residual serum specimens collected for routine laboratory testing by an academic medical center laboratory during May 17 through September 19, 2020. Seroprevalence by calendar month was standardized to the state population by race/ethnicity; cumulative numbers of infections were estimated by extrapolating seroprevalence to all those aged <18 years in Mississippi. Serum specimens from 1,603 individuals were tested; 175 (10.9%) were positive for SARS-CoV-2 antibodies. Among 1,579 (98.5%) individuals for whom race/ethnicity was known, the number testing positive was 16 (23.2%) of 69 Hispanic individuals, 117 (13.0%) of 901 non-Hispanic Black individuals and 30 (5.3%) of 565 non-Hispanic White individuals. Population-weighted seroprevalence estimates among those aged <18 years increased from 2.6% in May to 16.9% in September 2020. Cumulative numbers of infections extrapolated from seroprevalence data, however, were estimated at 117,805 (95% confidence interval [CI] = 68,771–168,708), suggesting that cases in children and adolescents are much higher than what was reported to the Mississippi State Department of Health (9,044 cases during this period). Further data to appreciate the burden of pediatric disease to inform public health policy is urgently needed.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialde-identified samples analyzed onlyFunding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (Activity was determined to meet the requirements of public health surveillance as defined in 45 CFR 46.102(l)(2).) The project was also reviewed and approved by the University of Mississippi Medical Center Institutional Review Board through the expedited review procedure.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are included in the manuscript.